Semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GIP/GLP-1 receptor agonist) are the two most effective incretin-based therapies for type 2 diabetes and obesity. While both achieve substantial HbA1c reduction and weight loss, they differ in efficacy magnitude, cardiovascular outcome data, cost, and patient-specific response patterns. Optimal patient selection requires matching individual characteristics to each agent’s strengths.
| Parameter | Semaglutide (Ozempic) | Tirzepatide (Mounjaro) |
|---|
| HbA1c reduction | −1.0 to −1.8% | −1.5 to −2.4% |
| Weight loss | 3–5 kg | 5–9 kg |
| FPG reduction | 30–60 mg/dL | 40–70 mg/dL |
| Time in range (CGM) | +10–15% | +15–20% |
| MACE reduction | 26% (SUSTAIN-6) | Pending (SURPASS-CVOT) |
| Parameter | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|
| Weight loss at 68 weeks | 12–15% | 15–22% |
| ≥10% weight loss | 50–60% | 65–80% |
| ≥15% weight loss | 30–40% | 50–60% |
| ≥20% weight loss | 15–20% | 35–45% |
| Waist circumference reduction | 8–12 cm | 10–16 cm |
| Patient Characteristic | Rationale |
|---|
| Established cardiovascular disease | SUSTAIN-6, SELECT trial CV data |
| Need for proven CV benefit | 26% MACE reduction (SELECT) |
| GLP-1 RA naïve | Lower cost, extensive real-world data |
| Cost sensitivity | Lower list price (Ozempic vs Mounjaro) |
| Oral formulation preference | Rybelsus available |
| Prior GLP-1 RA failure | Different mechanism than dual agonist |
| Hypoglycemia concern | Low hypoglycemia risk as monotherapy |
| CKD with proteinuria | SELECT trial renal subgroup data |
| Patient Characteristic | Rationale |
|---|
| Higher HbA1c (>9%) | Greater glucose-lowering efficacy |
| Obesity with BMI >35 | Superior weight loss (15–22%) |
| Prior GLP-1 RA suboptimal response | Dual GIP/GLP-1 mechanism |
| Metabolic syndrome (multiple criteria) | Greater metabolic improvement |
| NASH/NAFLD (off-label) | Greater hepatic fat reduction |
| Need for maximum weight loss | Highest weight loss efficacy |
| Higher fasting glucose | Greater FPG reduction |
| Insulin-resistant phenotype | GIP component enhances insulin sensitivity |
| Patient Profile | Semaglutide | Tirzepatide | Recommendation |
|---|
| T2DM, HbA1c 7.5%, BMI 30, no CV disease | Excellent | Excellent | Either (cost may decide) |
| T2DM, HbA1c 9.5%, BMI 35, no CV disease | Good | Excellent | Tirzepatide preferred |
| T2DM, HbA1c 8%, BMI 30, prior MI | Excellent | Good | Semaglutide preferred |
| Obesity, BMI 40, no diabetes | Excellent | Excellent | Tirzepatide preferred (greater weight loss) |
| Obesity, BMI 32, prior CV event | Excellent | Good | Semaglutide preferred |
| T2DM + NASH | Good | Excellent | Tirzepatide preferred |
| T2DM + CKD (eGFR 45) | Good | Good | Semaglutide (more CV data) |
| Factor | Semaglutide | Tirzepatide | Preferred |
|---|
| Established ASCVD | 26% MACE reduction | Pending CVOT | Semaglutide |
| Heart failure (HFrEF) | SELECT subgroup | SURPASS-HF pending | Semaglutide |
| Peripheral arterial disease | SELECT subgroup | Limited data | Semaglutide |
| Atrial fibrillation | Limited data | Limited data | Neither preferred |
| eGFR | Semaglutide | Tirzepatide | Preferred |
|---|
| >60 | Safe | Safe | Either |
| 45–59 | Safe | Safe | Either |
| 30–44 | Use with caution | Limited data | Semaglutide |
| <30 | Limited data | Limited data | Avoid both |
| Component | Semaglutide Effect | Tirzepatide Effect | Preferred |
|---|
| Hyperglycemia | ↓ HbA1c 1.0–1.8% | ↓ HbA1c 1.5–2.4% | Tirzepatide |
| Obesity | ↓ 3–5 kg (DM), 12–15% (obesity) | ↓ 5–9 kg (DM), 15–22% (obesity) | Tirzepatide |
| Hypertension | ↓ 3–5 mmHg | ↓ 5–8 mmHg | Tirzepatide |
| Dyslipidemia | ↓ TG 15–20% | ↓ TG 20–30% | Tirzepatide |
| NAFLD/NASH | ↓ hepatic fat | ↓ hepatic fat (greater) | Tirzepatide |
| Prior Therapy | Semaglutide Response | Tirzepatide Response | Strategy |
|---|
| GLP-1 RA naïve | Excellent | Excellent | Either |
| Liraglutide suboptimal | Good | Excellent | Tirzepatide preferred |
| Dulaglutide suboptimal | Excellent | Excellent | Either |
| Oral semaglutide suboptimal | Inject (different route) | Excellent | Tirzepatide preferred |
| SGLT2i suboptimal | Add semaglutide | Add tirzepatide | Either |
| Prior Intolerance | Semaglutide | Tirzepatide | Notes |
|---|
| Nausea (liraglutide) | May recur | May recur | Titrate slowly |
| GI intolerance (dulaglutide) | May recur | May recur | Consider lower starting dose |
| Injection site reactions | Similar | Similar | Rotate sites |
| Pancreatitis (GLP-1 RA) | Contraindicated | Contraindicated | Both avoid |
| Factor | Semaglutide | Tirzepatide | Clinical Implication |
|---|
| Higher baseline BMI | Yes | Yes | Greater absolute loss |
| Younger age | Yes | Yes | Better response |
| No prior GLP-1 RA | Yes | Yes | Naïve patients respond better |
| Female sex | Modest advantage | Modest advantage | Slight advantage |
| Non-smoker | Yes | Yes | Better adherence |
| Higher baseline HbA1c | Yes | Yes | Correlates with metabolic improvement |
| Definition | Semaglutide | Tirzepatide | Strategy |
|---|
| <5% weight loss at 16 weeks | 20–25% | 10–15% | Maximize dose, assess adherence |
| <3% weight loss at 16 weeks | 10–15% | 5–10% | Consider switch |
| Weight regain after initial loss | 15–20% | 10–15% | Assess adherence, lifestyle |
| Factor | Semaglutide | Tirzepatide | Impact |
|---|
| Monthly cost (US) | $935–1,349 | $1,023–1,059 | Semaglutide (Ozempic) lower |
| Insurance coverage | Variable | Variable | Check formulary |
| Patient assistance | Available | Available | Manufacturer programs |
| Copay assistance | Available | Available | May reduce out-of-pocket |
| Oral option | Yes (Rybelsus) | No | Oral preference → semaglutide |
| Week | Dose | Assessment |
|---|
| 1–4 | 0.25 mg/week | Tolerability |
| 5–8 | 0.5 mg/week | GI side effects |
| 9–12 | 1.0 mg/week | HbA1c, weight |
| 13+ | 2.0 mg/week (if needed) | Maximum efficacy |
| Week | Dose | Assessment |
|---|
| 1–4 | 2.5 mg/week | Tolerability |
| 5–8 | 5 mg/week | GI side effects |
| 9–12 | 7.5 mg/week | HbA1c, weight |
| 13–16 | 10 mg/week | Efficacy assessment |
| 17+ | 15 mg/week (if needed) | Maximum efficacy |
Patient selection between semaglutide and tirzepatide should consider cardiovascular risk (semaglutide preferred for established ASCVD), glycemic severity (tirzepatide preferred for HbA1c >9%), weight loss magnitude (tirzepatide preferred for BMI >35 or need for >15% weight loss), and cost (semaglutide may be lower). Both agents are highly effective, and the optimal choice depends on the individual patient’s comorbidity profile, treatment history, and goals.
